The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
By enrolling patients with unresectable Portal venous tumor emboli adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous or intraoperative IRE for unresectable Portal venous tumor emboli.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
15
Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
Fuda Cancer Hospital
Guangzhou, Guangdong, China
Safety (adverse effects)
adverse effects
Time frame: 6 month
Efficacy (percentage of lesions that show no sign of recurrence 12 months after IRE)
The primary objective of this project is to evaluate the efficacy (percentage of lesions that show no sign of recurrence 12 months after IRE)
Time frame: 12 months
Voltage (A minimum and maximum range of voltage for safe and effective IRE)
A minimum and maximum range of voltage for safe and effective IRE will be analyzed for optimal choice.
Time frame: 3 months
Progress free disease (PFS)
Patients will be followed for 12 months after IRE for PFS assessing.
Time frame: 12 months
Overall survival (OS)
Patients will be followed for 36 months after IRE for OS analyzed.
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.